- AI-driven skin cancer reconstruction clinical data unveiled in Bremen on May 7 (local time)
- Two-year long-term follow-up confirms "recurrence-free regeneration" with functional and aesthetic recovery
- Platform expansion beyond diabetic foot ulcers into skin cancer reconstruction; strategic European partnerships accelerated

▲ Photo: ROKIT Healthcare EWMA 2026 Booth

ROKIT Healthcare (KOSDAQ: 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, will present groundbreaking clinical outcomes in skin cancer regenerative therapy at EWMA 2026 (European Wound Management Association), Europe's largest wound care congress.

During the congress, held in Bremen, Germany from May 6–8, ROKIT Healthcare will exhibit its AI regeneration platform and deliver an official presentation on May 7, sharing the results of "Autologous adipose tissue regeneration using AI bioprinting following skin cancer resection: 1–2 year long-term follow-up outcomes" with medical professionals and industry stakeholders from around the world.

■ Two Years of Data Prove Regeneration — Innovating Beyond Simple Reconstruction

The centerpiece of the presentation is post-treatment prognostic data from patients tracked over one to two years.

Conventional skin cancer treatment has relied on skin grafting or simple suturing following tumor resection — approaches associated with scarring, reduced sensation, and functional deficits.

In contrast, ROKIT Healthcare's AI regeneration technology utilizing autologous adipose tissue demonstrated compelling clinical efficacy: ▲ 0% cancer recurrence rate within a maximum 2-year follow-up period, ▲ functional and aesthetic restoration of the resected area, and ▲ sensory recovery with minimal scarring. The results have earned high praise from specialists for establishing long-term safety that goes well beyond a one-time treatment.

■ The EUR 1.3 Trillion European Non-Melanoma Skin Cancer Market — Competing on Value and Efficiency

Europe is one of the regions with the highest skin cancer incidence in the world. According to market research, the European non-melanoma skin cancer (NMSC) treatment market reached approximately USD 890 million (approximately KRW 1.3 trillion) in 2025.

Rather than relying on costly artificial skin or complex surgical procedures, ROKIT Healthcare offers a low-cost, high-efficiency alternative that prints and regenerates tissue from the patient's own cells on-site — positioning the company as an innovative model for relieving the economic burden on European health authorities.

■ Live Demos for Global KOLs and Expanding Local Networks

ROKIT Healthcare will leverage its exhibition booth to drive tangible business growth. The company will conduct live demonstrations of its AI regeneration platform, showcasing the entire process from wound scanning to the output of customized regenerative patches — providing direct proof of its technological capabilities.

Simultaneously, the company will hold one-on-one meetings with major hospitals and large medical device distributors in key Western European markets including Germany and France, accelerating the establishment of pan-European partnerships and supply chain development. Starting from this congress, ROKIT Healthcare plans to sign preliminary agreements with three partners across Europe and the Middle East in the first half of the year.

The company also plans to collaborate with global key researchers and stakeholders to expand multi-center clinical trials in Europe, building on these results to advance discussions around inclusion in standard treatment guidelines and further consolidating its global clinical network.

■ Limitless Platform Scalability — A Milestone in Maximizing Corporate Value

This presentation marks a decisive proof point of ROKIT Healthcare's platform scalability. It demonstrates that the company's DFU (diabetic foot ulcer) treatment technology — already commercialized in global markets — has successfully translated into the advanced domain of skin cancer reconstruction. This is expected to serve as a strong foundation for future entry into high-value organ regeneration markets, including cartilage and kidney.

A ROKIT Healthcare spokesperson stated, "The two-year long-term follow-up results confirm that ROKIT Healthcare's technology goes beyond temporary wound healing — demonstrating its value and technical prowess in the precision medicine field of cancer reconstruction. Building on this congress, we will expand our market share in Europe and establish ourselves as a company that sets the standard for the global regenerative medicine market."